205 related articles for article (PubMed ID: 24255083)
61. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.
Santucci R; Levêque D; Kemmel V; Lutz P; Gérout AC; N'guyen A; Lescoute A; Schneider F; Bergerat JP; Herbrecht R
Anticancer Res; 2010 Mar; 30(3):963-5. PubMed ID: 20393020
[TBL] [Abstract][Full Text] [Related]
62. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function.
Hempel L; Misselwitz J; Fleck C; Kentouche K; Leder C; Appenroth D; Rost M; Zintl F
Med Pediatr Oncol; 2003 Jun; 40(6):348-54. PubMed ID: 12692801
[TBL] [Abstract][Full Text] [Related]
63. Do not exclude glucarpidase too soon in the context of high-dose methotrexate induced nephrotoxicity.
Dijkman MA; de Lange DW; de Vries I
Neth J Med; 2018 May; 76(4):204. PubMed ID: 29845950
[No Abstract] [Full Text] [Related]
64. Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
Widemann BC
Pediatr Blood Cancer; 2015 Sep; 62(9):1512-3. PubMed ID: 25940351
[No Abstract] [Full Text] [Related]
65. Methotrexate-induced periorbital radiation recall.
Kiel PJ; Jones KL
Ann Pharmacother; 2011 Jan; 45(1):133. PubMed ID: 21205951
[No Abstract] [Full Text] [Related]
66. High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?
Meyers PA; Flombaum C
J Clin Oncol; 2011 Mar; 29(7):e180; author reply e181. PubMed ID: 21220601
[No Abstract] [Full Text] [Related]
67. Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients.
Krüger C; Engel N; Reinert J; Alsdorf W; Fiedler W; Dierlamm J; Bokemeyer C; Langebrake C
Pharmacotherapy; 2020 May; 40(5):479-483. PubMed ID: 32239519
[TBL] [Abstract][Full Text] [Related]
68. [Accidental shortening time of high dose methotrexate infusion: case report and literature review].
Charfi R; Salouage I; Trabelsi S; Zarrouk M; Gaïes E; Jebabli N; Meddeb B; Lakhal M; Klouz A
Ann Biol Clin (Paris); 2013; 71(2):219-22. PubMed ID: 23587592
[TBL] [Abstract][Full Text] [Related]
69. Weekly oral methotrexate therapy: raise awareness of fatal dosing errors.
Prescrire Int; 2013 May; 22(138):126. PubMed ID: 23819175
[No Abstract] [Full Text] [Related]
70. Methotrexate pulmonary toxicity.
Lateef O; Shakoor N; Balk RA
Expert Opin Drug Saf; 2005 Jul; 4(4):723-30. PubMed ID: 16011450
[TBL] [Abstract][Full Text] [Related]
71. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.
Buchen S; Ngampolo D; Melton RG; Hasan C; Zoubek A; Henze G; Bode U; Fleischhack G
Br J Cancer; 2005 Feb; 92(3):480-7. PubMed ID: 15668713
[TBL] [Abstract][Full Text] [Related]
72. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
Fermiano M; Bergsbaken J; Kolesar JM
Am J Health Syst Pharm; 2014 May; 71(10):793-8. PubMed ID: 24780487
[TBL] [Abstract][Full Text] [Related]
73. Early intervention is important when administering glucarpidase for methotrexate intoxication. Author's reply.
Miceli G; Daidone M; Corpora F; Di Gaudio F; Tuttolomondo A;
Eur J Intern Med; 2024 Jun; 124():152-153. PubMed ID: 38685140
[No Abstract] [Full Text] [Related]
74. [Therapeutic drug monitoring of methotrexate after its administration in high-dose protocols].
Le Guellec C; Blasco H; Benz I; Hulin A;
Therapie; 2010; 65(3):163-9. PubMed ID: 20699066
[TBL] [Abstract][Full Text] [Related]
75. Anaphylaxis during the first course of high-dose methotrexate: a case report and literature review.
Pugi A; Benemei S; Vietri M; Tondo A; Calvani AM; Mugelli A; Vannacci A; Lapi F
J Clin Pharm Ther; 2012 Apr; 37(2):245-8. PubMed ID: 21569069
[TBL] [Abstract][Full Text] [Related]
76. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.
McBride A; Antonia SJ; Haura EB; Goetz D
J Pharm Pract; 2012 Aug; 25(4):477-85. PubMed ID: 22550162
[TBL] [Abstract][Full Text] [Related]
77. Genetics of high-dose methotrexate-induced oral mucositis: current perspectives.
Heil SG
Pharmacogenomics; 2019 Jun; 20(9):621-623. PubMed ID: 31250729
[No Abstract] [Full Text] [Related]
78. Pharmacokinetics and Pharmacodynamics of Glucarpidase Rescue Treatment After High-dose Methotrexate Therapy Based on Modeling and Simulation.
Kimura T; Fukaya Y; Hamada Y; Yoshimura K; Kawamoto H
Anticancer Res; 2023 May; 43(5):1919-1924. PubMed ID: 37097666
[TBL] [Abstract][Full Text] [Related]
79. Acute hypokalemic tetraparesis induced by intravenous methotrexate.
Thuss-Patience PC; Peters U; Jurkat-Rott K; Pink D; Kretzschmar A; Dörken B; Reichardt P
J Clin Oncol; 2003 May; 21(9):1896-7. PubMed ID: 12721279
[No Abstract] [Full Text] [Related]
80. Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function.
Phillips M; Smith W; Balan G; Ward S
J Clin Pharmacol; 2008 Mar; 48(3):279-84. PubMed ID: 18192538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
